Cyberattack Alert - Severe WARNINGS & CAUTIONS to All Members
NASDAQ 7,234.31 -254.63 (-0.07%) DJIA 24,964.75 -254.63 (-1%) S&P 500 2,716.26 -15.96 (-0.58%) 20/02/2018 16:59

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Bristol-Myers Squibb Company

13/02/2018 17:41

NEW YORK

Levi & Korsinsky announces it has commenced an investigation of Bristol-Myers Squibb Company (NYSE:BMY) concerning possible violations of federal securities laws.

On August 5, 2016, Bristol-Myers revealed that its CheckMate-026 trial exploring the use of Opdivo (nivolumab) as monotherapy failed to meet its primary endpoint of progression-free survival. Following this news, Bristol-Myers stock fell 16% to close at $63.28 per share on August 5, 2016. Then on October 9, 2016, Bristol-Myers revealed the final primary analysis of CheckMate-026, and that the overall Opdivo survival was only 14.4 months compared to chemotherapy's 13.2 months. Following this news, Bristol-Myers stock dropped over 10%, to close at $49.81 per share on October 10, 2016. To obtain additional information, go to:

http://www.zlkdocs.com/BMY-Info-Request-Form-6459

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
Tel: 212-363-7500
Toll Free: 877-363-5972
Fax: 212-363-7171
www.zlk.com

More News


Ziopharm Oncology to Announce Fourth Quarter and Full Year 2017 Year-end Financial Results and Host Conference Call on March 1

13/02/2018 13:15

BOSTON, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), today anno...

Cott to acquire Crystal Rock Holdings

13/02/2018 13:19

Cott Corporation (NYSE: COT ) signs a $35M deal to acquire Crystal Rock Holdings (NYSEMKT: C...

Free Research Report as Shutterfly's Quarterly Earnings Surged 18.2%; Surpassed Expectations

13/02/2018 13:20

Stock Monitor: Bright Horizons Family Solutions Post Earnings Reporting LONDON, UK / ...


Terms and Conditions | Privacy Statement
Financial.org is an educational platform. We DO NOT deal with securities and receive any financial benefits from Financial Products & Service Providers.